High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications

Eastern Mediterranean Health Journal

Volumn 13, Issue 5, 2007, Pages 1053-1059

  Ghader, Fashid R ^a   Kousarian, M ^a   Farzin, D ^a  

^a Booali Hospital   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CALCITRIOL; CALCIUM; CAPTOPRIL; DEFEROXAMINE; DIGOXIN; FERRITIN; FOLIC ACID; FUROSEMIDE; HEMOGLOBIN; PENICILLIN G;

ADOLESCENT; ADULT; ARTICLE; AUDITORY SCREENING; CARDIOMYOPATHY; CARDIOVASCULAR SYMPTOM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; FERRITIN BLOOD LEVEL; HEART FUNCTION TEST; HEMOGLOBIN BLOOD LEVEL; HUMAN; PHYSICAL EXAMINATION; THALASSEMIA; TREATMENT DURATION; URTICARIA; VISUAL SYSTEM EXAMINATION;

EID: 37849052998     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2007.13.5.1053     Document Type: Article

References (25)

1. Miller DR, Baehner RL, Miller LP, eds. Blood disease in infancy & childhood. St Louis, Mosby, 1995:443-82.
2. Allen HD et al. 'Moss and Adam's heart disease in infants, children and adolescents, 6th ed. Philadelphia, Lippincott Williams & Wilkins, 2000:1263.
3. Behrman RE, Kliegman RM, Jenson HB. Nelson textbook of pediatrics, 17th ed. Philadelphia, WB Saunders, 2000:1484-5.
4. Galanello R. Iron chelation: new therapies. Seminars in hematology, 2001, 38(1 suppl. 1):73-6.
5. Riva A et al. Type 3 hemochromatosis. European journal of hematology, 2004, 72:370-4.
6. Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent. Journal of pediatrics, 1997, 130(1):86-8.
7. Olivieri NF, Brittenham GM. Iron chelating therapy and the treatment of thalassemia. Blood, 1997, 89(3):739-61.
8. Loebstein R et al. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone. British journal of haematology, 1997, 98(3):597-600.
9. Mazza P et al. Oral iron chelating therapy. Haematologica, 1998, 83(6):496-501.
10. Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best practice & research. Clinical haematology, 2005, 18(2):289-98.
11. DeSwarte-Wallace J, Groncy PK, Finklestein JZ. Iron chelation with deferoxamine: comparing the results of a critical pathway to a national survey. Journal of pediatric hematology/oncology, 1999, 21 (2): 136-41.
12. Davis BA, Porter JB. Long term outcome of continuous 24-hr DFO infusion. Blood, 2000, 95(4): 1229-36.
13. Boturao-Neto E, Marcopito LF, Zago MA. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. Brazilian journal of medical and biological research, 2002, 35(11): 1319-28.
14. Miskin H et al. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. European journal of hematology, 2003, 70(6):398-403.
15. Ehsani MA, Hedayati AA, Seighali AF. Evaluation of high dose intravenous Desferal therapy in thalassemia major patients with heart failure. Paper presented at the 9th International Conference on Thalassemia and Hemoglobinopathies, 056, 15-19 October, 2003, Palermo, Italy (http://www.soste.org/archivio/docs/TIF.pdf, accessed 12 February 2007).
16. Di Gregorio F et al. Chelazione intensiva per via venosa in pazienti talassemici ipersiderotici [intensive intravenous chelation in thalassemic patients with iron overload]. Minerva pediatrica, 1988, 50(3):81-5.
17. Hatziliami A et al. Heart MRI findings in transfusion-dependent thalassemia major patients. Paper presented at the 9th International Conference on Thalassemia and Hemoglobinopathies, 056, 15-19 October, 2003, Palermo, Italy.
18. Peng CT, Wu KH, Tsai C.H. Combined therapy with deferiprone and desferrioxamine successfully regress severe heart failure in patients with beta thalassemia major. Paper presented at the 9th International Conference on Thalassemia and Hemoglobinopathies, 056, 15-19 October, 2003, Palermo, Italy (http://www.soste.org/archivio/docs/TIF.pdf, accessed 12 February 2007).
19. Haimovici R et al. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology, 2002, 109(1): 164-71.
20. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology, 2001:47-61.
21. Lai TYY. Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion. British journal of ophthalmology, 2006, 90:243-4
22. Dickerhoff R. Acute aphasia and loss of vision with desferrioxamine overdose. American journal of hematology and oncology, 1987, 9(3):287-6.
23. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet, 1983, 2(8343):181-4.
24. Porter JB. Deferoxamine pharmacokinetics. Seminars in hematology, 2001, 38(1 suppl. 1):63-8.
25. Kruck TP et al. High performance liquid chromatographic analysis of desferrioxamine. Journal of chromatography, 1988, 433:207-16.